Canada: Canada-EU Free Trade Deal: Intellectual Property Issues For The Pharmaceutical Industry

Last Updated: October 27 2013
Article by Xavier Van Overmeire and Sam Pathmasiri

Context

Canada and the European Union (the "EU") have signed a tentative deal to open markets and drop nearly all import taxes on everything from food to cars. Under the Comprehensive Economic Trade Agreement (the "CETA") and NAFTA, Canada will have preferential access to more than half of the world's economy. The agreement also provides for working groups to look at non-tariff barriers — regulations on health and sanitation, for example — that interfere with trade.

Such an economic agreement with the EU will provide Canadian pharmaceutical companies with preferential access to a market of 503 million consumers. CETA shall exceed the scope of the North American Free Trade Agreement (which is part of "first generation" series agreements), and inscribes itself as part of a new series of "second generation" agreements. CETA, as the agreements of first generation, continues to cover trade in goods and services. However, in the second generation agreements, added emphasis is placed on dismantling non-tariff barriers such as public procurements, the protection of IP rights, competition, mutual recognition of professional qualifications, sustainable development, environment, education and investment. This agreement will allow EU companies to compete with US exporters on the Canadian market by leveling the playing field, in addition to benefitting from preferential treatment going beyond NAFTA.

Main differences between Canada and the EU regarding IP

With respect to the protection of IP rights, CETA establishes standards which supersede those of the Agreement on Trade-Related Aspects of Intellectual Property Rights ("TRIPS"). For instance, the protection of IP rights has been particularly strengthened by extending the length of protection. In this respect, the EU and Canada have different levels of protection, as summarized in the following table:

In Canada, the patent's term was increased from 17 to 20 years in 1989 to comply with Canada's international commitments (including TRIPS1, which provides for a minimum of twenty years of protection). However, in practice and especially in the pharmaceutical industry, the length of commercial exploitation of patents is actually reduced due to clinical trials and obtaining the notice of compliance ("NOC"). In fact, the commercial life of a patent for an innovative drug is about ten years on average: which is half the term of patent protection in Canada. The approval period for a patent application can take four years and on average, it takes six years to complete the clinical trials and obtain a NOC. Note also that such delays are higher than in other industrialized countries.

In Europe, the patent regime takes into account the "commercial" shortening of the patent lifespan resulting from the delays in obtaining an authorization to commercialize (the "AC") before the products are put on the market. In order to promote research and development of innovative drugs, the EU compensates for the loss of time caused by the administrative authorization process through the "Certificate of Complementary Protection", which can extend the lifetime of a patent for a maximum of five years where the application meets certain criteria. The Canadian regime does not provide for such an extension on patent protection. 

In addition, the EU regime provides for a ten year protection period on the clinical data collected by innovative pharmaceutical industries on the condition that they comply with their obligations under the AC. This protection covers data collected by a company during its clinical trials.  However, after a period of eight years, the clinical data pertaining to the original drug can be used to prepare an AC request by the generic industry, which can then be approved at the expiration of the ten year protection period. Furthermore, an additional protection of one year is available to the original drug manufacturer if it can demonstrate that during the initial eight years of commercial exclusivity it had obtained an AC for one or several new therapeutic indications.

Furthermore, to encourage the pharmaceutical industry to develop their research with respect to drugs intended to treat rare diseases and "orphan" drugs, the EU chose to grant innovative companies a full exclusivity period of ten years.

Thus, the level of protection is higher in Europe and much emphasis is placed on protecting R&D results.

The differences benefit the Canadian generic industry. Indeed, the lower level of protection in Canada actually benefits the generic industry and its competitiveness on the European market, since it allows companies to commercialize their generics before their European competitors. However, while this latter segment of the pharmaceutical industry stands to benefit, the innovative companies remain adversely affected by the Canadian regime as the comparatively lesser duration of protection limits their commercial exclusivity in Canada. Since Europe has longer protection of intellectual property rights, the generic drugs produced by a European company are available on the European market at a later time in comparison to Canada.

Negotiations requirements of the EU

During negotiations, the EU had made three requests: (1) An extension of the legal duration of patents; (2) The duration of the exclusive data protection must expand the scope of its application and shall be extended to at least ten years from the issuance of the Notice of Compliance Regulations (the "NOC") and to at least eleven years if, during the eight first years following the issuance of the NOC, the innovative pharmaceutical company obtains an authorization to process one or several new therapeutic indications; (3)The reinforcement of patent holder rights under the NOC regulations by offering a right of appeal of any Court decision granting NOC to commercialization of a generic drug.

It will be interesting to see if the provision of the final text, when it is published, will include such requirements. Meeting these EU requirements would therefore in turn require many modifications to the Canadian legislation, namely the Food and drug Regulation, the Notice of Compliance Regulations and the Patent Act. It can possibly lead to the creation of new regulations supporting those modifications.

Conclusion

The CETA can significantly modify the Canadian IP landscape for the pharmaceutical industry. This has brought about  significant controversy regarding the balance between the protection granted to patent holders on one side and the accessibility (in terms of price) for the consumer on the other side.

From the innovative pharmaceutical industry's perspective, changes leading to an extension of the exclusive commercialization period would allow it to better absorb the cost of research. This would in turn represent an incentive for innovators to push their research even further. This might promote greater investment in R&D in Canada. However, this hypothesis is tempered by the fact that according to some observers, there is no direct correlation between an extension of IP protection and increased investment in R&D. 

Nevertheless, this extension of the IP protection duration would be a significant challenge for the generic industry in Canada. Similarly, the delay in the commercialization of the generic products will lead to a rise in cost for medication and will increase costs for provincial authorities, which bear this burden since they will have to wait longer before having access to generic drugs.

About Dentons

Dentons is a global firm driven to provide you with the competitive edge in an increasingly complex and interconnected marketplace. We were formed by the March 2013 combination of international law firm Salans LLP, Canadian law firm Fraser Milner Casgrain LLP (FMC) and international law firm SNR Denton.

Dentons is built on the solid foundations of three highly regarded law firms. Each built its outstanding reputation and valued clientele by responding to the local, regional and national needs of a broad spectrum of clients of all sizes – individuals; entrepreneurs; small businesses and start-ups; local, regional and national governments and government agencies; and mid-sized and larger private and public corporations, including international and global entities.

Now clients benefit from more than 2,500 lawyers and professionals in 79 locations in 52 countries across Africa, Asia Pacific, Canada, Central Asia, Europe, the Middle East, Russia and the CIS, the UK and the US who are committed to challenging the status quo to offer creative, actionable business and legal solutions.

Learn more at www.dentons.com

Footnote

1. The WTO Agreement on TRIPS, negotiated during the Uruguay Round, which took place from 1986 to 1994, introduced, for the first time, rules relating to IP in the multilateral trading system. Section 33 requires a minim of 20 years protection for patents.

For more information, visit our Doing Business in Canada blog at www.doingbusinessincanada.com/

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. Specific Questions relating to this article should be addressed directly to the author.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
23 Oct 2018, Other, Toronto, Canada

Dentons and SheEO are coming together for an evening of #radicalgenerosity on October 23, 2017. Meet Vicki Saunders, Founder of SheEO, and learn about how SheEO is changing the landscape for female entrepreneurs.

23 Oct 2018, Seminar, Montreal, Canada

Dentons is pleased to invite you to join us for a breakfast seminar as part of the Les Matinées Dentons series on issues relevant to you and your business.

24 Oct 2018, Other, Toronto, Canada

If you build it, claims may come. Join the Dentons Construction group for breakfast and an informative discussion on current topics in construction law.

Similar Articles
Relevancy Powered by MondaqAI
Norton Rose Fulbright Canada LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Norton Rose Fulbright Canada LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions